FDA - Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products (Catapult's regulatory round-up - March)
Fiche du document
19 février 2024
- doi: 10.58079/vv4z
info:eu-repo/semantics/openAccess
Sujets proches
Immunologic deficiency Immune deficiency Immunological deficiency Products, Blood Blood componentsCiter ce document
adelage, « FDA - Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products (Catapult's regulatory round-up - March) », ELSIBI, ID : 10.58079/vv4z
Métriques
Partage / Export
Résumé
The Centre for Biologics Evaluation and Research (CBER) has issued a draft guidance to receive comments on revised recommendations for evaluating donor eligibility using individual risk-based questions. This draft guidance, when finalized will provide blood establishments that collect blood or blood components, including Source Plasma, with FDA’s revised donor deferral recommendations for individuals with increased risk for transmitting human immunodeficiency virus (HIV) infection. Published...